In response to the U.S. government’s proposed creation of a comprehensive regulatory framework, Reval understands and agrees with the need to better regulate the OTC derivatives market.  Better transparency, controls, and the ability to clear OTC derivative instruments would help prevent future systemic risk.  However, the broad regulatory reform suggested for all OTC derivatives may in fact increase risk in the system.